Poland· PL-100381571
Aripiprazole Aurovitas
A aripiprazole product containing aripiprazolum, registered in Poland by Aurovitas Pharma Polska Sp. z o.o.. The same ATC class is registered in 18 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Aripiprazole is registered in 18 of 19 countries.
Countries holding a registration under ATC N05AX12 (aripiprazole), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 11 of them publish a price we can compare per daily dose
Aripiprazole · ATC N05AX12
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aripiprazole costs, country by country.
Normalised to the WHO defined daily dose (15 mg), the median price runs from $0.15 in United States to $3.12 in Switzerland — a ×21 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aripiprazole · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.12
- IT Italy$1.19
- FR France$1.06
- US United States$0.15 (acquisition cost)
The record
At a glance
URPL (Poland)- Active substance
- Aripiprazolum
- Manufacturer
- Aurovitas Pharma Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N05AX12
- ATC class
- Aripiprazole
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- July 26, 2026
Packs & prices · 2
- gtin05909991339982
- gtin05909991339975
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
468 interactions on record for aripiprazole.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aripiprazole · interactions on record
468 records
- 11 severe
- 339 moderate
- 2 minor
- 67 info
Most severe, free to view
- MetoclopramideA03FA01severe
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
- FamotidineA02BA03moderate
49 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05AX12
Aripiprazole, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d1dfa799-5517-48f2-bb0c-c1862c3d5434 GET /v1/drugs/d1dfa799-5517-48f2-bb0c-c1862c3d5434?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "30 mg",
"packaging": "05909991339975 ¦ Rp ¦ 123739\n28 tabl.\n05909991339982 ¦ Rp ¦ 123740\n56 tabl.",
"substance": "Aripiprazolum 30 mg",
"common_name": "Aripiprazolum",
"pl_product_id": "100381571",
"pozwolenie_nr": "24151",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about aripiprazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.